High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.
about
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.Automatic classification of protein structures using low-dimensional structure space mappingsProtection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy.Antigen signal strength during priming determines effector CD4 T cell function and antigen sensitivity during influenza virus challenge.A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40LProgress on new vaccine strategies for the immunotherapy and prevention of cancer.Strategies for designing and optimizing new generation vaccines.The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?Emerging vaccine informatics.Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflageProgress on new vaccine strategies against chronic viral infectionsA push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cellsHelper cell-independent antitumor activity of potent CD8(+) T cell epitope peptide vaccines is dependent upon CD40L.Strategies for optimizing targeting and delivery of mucosal HIV vaccines.Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.Structural basis for degenerate recognition of natural HIV peptide variants by cytotoxic lymphocytes.Modification of the inhibitory amino acid for epitope peptide binding onto major histocompatibility complex class II molecules enhances immunogenicity of the antigen.Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.Cancer vaccine strategies: translation from mice to human clinical trials.Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2.Tools for Vaccine Design: Prediction and Validation of Highly Immunogenic and Conserved Class II Epitopes and Development of Epitope-Driven Vaccines
P2860
Q27472925-7837B314-95C1-4BDE-B4E5-26B4826F0EA6Q30359369-53BAC707-03E9-4845-8F7C-6E60BEC6AA86Q30449492-F661AAD9-7764-4E49-B3AE-10A1C87CEF75Q33567970-D5BCECED-0DF2-44FA-87BA-F5DA40F1D703Q34146590-D18F498A-408D-4CB4-A765-871DAA4F4A54Q34191248-241697DB-406C-41E1-BA3F-E78F9F79CD97Q34328457-D25E77F3-EF54-45D3-BD23-2EA331709571Q34572198-DAFCC001-3068-4144-BB0C-552F7BDEA84FQ34632089-DCD67125-230B-4A64-974D-B6421996FF18Q35100809-9A0F7821-7F59-4654-AD77-8E14E2C1E9E2Q35221584-8B7AF4FD-A1B6-4C77-B914-FDFE6EC1B9B3Q35864857-3096CFE5-5F29-4028-A5D3-DBB52C76986AQ35871793-6ED379D4-4600-4B04-8687-1C6C4E0C61CDQ36663607-2F76ACF8-4BE5-4FDC-917D-28DB27D4DF2FQ37221714-EF857793-28D0-446D-B031-EDFFB3157248Q37499652-6F45F870-A37B-48BD-986C-2257EB1703F7Q37554135-461F055B-9EF2-4AEF-B7D9-7B2287F4197AQ37729146-E58470EB-9641-4A5E-AA04-7608084D9DF2Q39093893-53396BFE-9F5B-43A5-ADF3-7A097554B77BQ40279655-9B110F02-501C-4F30-88FB-7B27313F05BFQ44761480-BFA3543C-A160-4127-B77B-B8EB0E77E1D4Q45590933-A3F18DBE-567C-4D2A-9AE7-1846F5081825Q48295639-A887DA70-72E9-43F6-BC45-6C3C4AB7D15CQ50991984-CE1968FE-8CEF-4F92-8099-6F2D9C27CB43Q51956042-6864B30B-FFBF-464C-8207-C85E895A2333Q57537566-A610F719-62A5-4C32-901E-D9C657D1C485
P2860
High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
High-affinity T helper epitope ...... ction against viral infection.
@ast
High-affinity T helper epitope ...... ction against viral infection.
@en
type
label
High-affinity T helper epitope ...... ction against viral infection.
@ast
High-affinity T helper epitope ...... ction against viral infection.
@en
prefLabel
High-affinity T helper epitope ...... ction against viral infection.
@ast
High-affinity T helper epitope ...... ction against viral infection.
@en
P2093
P2860
P356
P1476
High-affinity T helper epitope ...... ction against viral infection.
@en
P2093
E K Thomas
I M Belyakov
J A Berzofsky
J D Ahlers
P2860
P304
P356
10.1172/JCI200113463
P407
P577
2001-12-01T00:00:00Z